Hovilpri FDA Approval: 63% Healing Rate Revealed
Hovilpri FDA approval gives immunocompromised adults an oral option for HSV lesions that resist standard antivirals. Trial data, dosing, safety, launch.
Hovilpri FDA approval gives immunocompromised adults an oral option for HSV lesions that resist standard antivirals. Trial data, dosing, safety, launch.